Trials / Completed
CompletedNCT05896683
A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
A Phase 1, Open-label, Randomized, 2-Part, 2-Way Crossover Study in Healthy Adult Participants to Assess the Relative Bioavailability of Tablet Formulations of Lazertinib (JNJ-73841937)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the extent of availability of drug to the body of four different lazertinib tablet formulations at a single oral dose under fasted conditions in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lazertinib | Lazertinib will be administered orally. |
Timeline
- Start date
- 2023-05-30
- Primary completion
- 2023-09-01
- Completion
- 2023-09-01
- First posted
- 2023-06-09
- Last updated
- 2025-02-03
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT05896683. Inclusion in this directory is not an endorsement.